A totally new kind of erectile dysfunction drug is to be introduced on the Eastern markets by a UAE-based pharmaceutical company, giving men more options to deal with impotence.

Vitaros

Vitaros(R), an ED drug by Elis, a UAE-based pharmaceutical company, will be presented to the Government and pharmacists in the Middle East, Africa and CIS countries. This drug is already approved in Canada and several other countries as the first topical ED treatment. The major advantage of this drug over other oral and other ED therapies is its form. Vitaros(R) is a cream that is applied directly to the penis, rather than a pill that takes longer to absorb. Also, it has less side effects and gives men more choices.

Commenting on the introduction of the drug onto the new markets, Mr. Assouma of Elis, said: “Because of Elis’ proven marketing strategies and the patient responses we’ve already experienced as part of our sampling program, we anticipate strong sales of Vitaros(R) in this region, where the total market for erectile dysfunction drugs is more than $100 million per year.”

The manufacturer of the new erectile dysfunction drug, Avanafil, recently posted positive results from the drug’s clinical trials.

Avanafil

Last Tuesday, Vivus, a pharmaceutical company, posted positive results from a trial of its new erectile dysfunction drug that is currently undergoing the review of the US Food and Drug Administration.

Avanafil, the experimental impotence drug, was proved to help 71% of patients to start the sexual intercourse within 15 minutes and after 6 hours after dosing.

In the 80% of cases, the 200-mg dose was sufficient for men suffering from ED, to get and maintain healthy erection.

The results of the clinical trial were published in the Journal of Sexual Medicine.

Commenting on the findings, Irwin Goldstein, the investigator of Avanafil, said: “While PDE-5 inhibitors are currently used as first-line therapy for treatment of erectile dysfunction in the general population, what’s new and novel about avanafil is that it has a fast onset of action and high selectivity.”

The drug will appear in US pharmacies provided it gets the approval from US FDA.

The European high court ruled that a popular energy drink known as Viaguara has no right to register its trademark in the EU.

Viaguara Energy Drink

Recently, the confusion caused by the producer of an energy drink Viaguara was averted as the EU High Court made the decision.

The company was refused the right to register a trademark for its Viaguara energy and alcoholic drink. The EU High Court ruled that there are several reasons for that.

First, the Viagura name gives the producer an opportunity “to take unfair advantage of the distinctive character or repute of the trademark Viagra.”

Second, Viagra is a medical drug used to treat erectile dysfunction. It is a prescription drug, meaning that it can be sold only to those patients who have been prescribed to take Viagra by a doctor. Any confusion related to the name of the drug might have serious medical consequences. “Even if the non-alcoholic drinks concerned do not actually have the same benefits as a drug to treat erectile dysfunction, the consumer will be inclined to buy them thinking that he will find similar qualities, such as an increase in libido,” said the representative of the EU High Court.

The manufacturer of Viagra, Pfizer, warmly welcomed the court ruling.